Back to News
Market Impact: 0.35
Alnylam's Brezosiran Lowers Mutant Huntingtin In Phase 1b Huntington's Trial
Source: Nasdaq
Healthcare & Biotech
Alnylam reported that investigational drug Brezosiran (formerly ALN-HTT02) reduced mutant huntingtin protein levels in an initial Phase 1b trial in patients with Huntington’s disease. The report provides no numerical reduction or clinical-outcome data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ALNY0.70
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Cumberland Pharmaceuticals stock tumbles on trial results